オピオイドリスクスコアリングにおけるアルゴリズムの不透明性と透明性のあるAI規制の必要性
Sherry Yun Wang1, Ryan Stofer2, Zhouzhou Chu2
1School of Pharmacy, Chapman University, Irvine, CA, USA. yunwang@chapman.edu.
Abstract:
NarxCare®, a proprietary opioid risk scoring system embedded in Prescription Drug Monitoring Programs (PDMPs), has generated significant patient complaints. We adhered to the technical specifications and applied them to PDMP and IQVIA PharMetrics® Plus Closed Health Plan claims database. Despite adding socioeconomic covariates, precision (0.01-0.32) was far below the reported benchmark of 0.75, and F1 scores (0.02-0.39) were also substantially lower than the benchmark value of 0.65, across all our reconstructed models.
関連する概念動画
Opioid Analgesics: Morphine and Other Natural Cogeners
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Drug Control Governance: Regulatory Bodies and Their Impact
Opioid Receptors: Overview
Analgesia and Pain Management
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
